Healthy Volunteer Study of Sildenafil Effects Upon Vision

This study has been completed.
Information provided by:
University of Cambridge Identifier:
First received: November 9, 2005
Last updated: NA
Last verified: December 2003
History: No changes posted
Patients sometimes report subjective visual effects when taking sildenafil. Our study set out to measure these in a controlled setting. Subjects were asked to detect patterns presented on a monitor screen.

Condition Intervention Phase
Drug: Sildenafil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Educational/Counseling/Training
Official Title: A Double-Blind, Randomised, Placebo Controlled Healthy Volunteer Study to Investigate the Nature and Origin of the Disturbance of Vision Induced by Single Oral Doses of Sildenafil

Resource links provided by NLM:

Further study details as provided by University of Cambridge:

Study Start Date: February 2002
Estimated Study Completion Date: June 2003

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria: male -

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00251784

Sponsors and Collaborators
University of Cambridge
Principal Investigator: Morris J Brown, MD University of Cambridge
Study Director: John Mollon, FRS University of Cambridge
  More Information Identifier: NCT00251784     History of Changes
Other Study ID Numbers: LREC 98/297 
Study First Received: November 9, 2005
Last Updated: November 9, 2005
Health Authority: United Kingdom: National Health Service

Additional relevant MeSH terms:
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Therapeutic Uses
Urological Agents
Vasodilator Agents processed this record on April 27, 2016